Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk

Science Translational Medicine

Volumn 6, Issue 248, 2014, Pages

  Moeckel, Douglas ^a   Jeong, Soon Soeg ^b   Sun, Xiaofeng ^c   Broekman, M Johan ^d,e   Nguyen, Annie ^a   Drosopoulos, Joan H F ^d,e   Marcus, Aaron J ^d,e   Robson, Simon C ^c   Chen, Ridong ^b   Abendschein, Dana ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b APT Therapeutics Inc ^*  (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; APYRASE; CLOPIDOGREL; PIPERAZINE DERIVATIVE; PRASUGREL; THIOPHENE DERIVATIVE; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR;

ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; COMPLICATION; CORONARY ARTERY BLOOD FLOW; DOG; DRUG EFFECTS; FIBRINOLYSIS; HEMORRHAGE; HUMAN; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PATHOPHYSIOLOGY; RISK FACTOR; THROMBOCYTE AGGREGATION; THROMBOSIS; TIME FACTOR; TREATMENT OUTCOME; VASCULAR PATENCY;

ADENOSINE DIPHOSPHATE; ANIMALS; APYRASE; CORONARY CIRCULATION; DOGS; FIBRINOLYSIS; HEMORRHAGE; HUMANS; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PIPERAZINES; PLATELET AGGREGATION; PRASUGREL HYDROCHLORIDE; RISK FACTORS; THIOPHENES; THROMBOSIS; TICLOPIDINE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 84905984055     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009246     Document Type: Article

References (51)

1. A. S. Go, D. Mozaffarian, V. L. Roger, E. J. Benjamin, J. D. Berry, W. B. Borden, D. M. Bravata, S. Dai, E. S. Ford, C. S. Fox, S. Franco, H. J. Fullerton, C. Gillespie, S. M. Hailpern, J. A. Heit, V. J. Howard, M. D. Huffman, B. M. Kissela, S. J. Kittner, D. T. Lackland, J. H. Lichtman, L. D. Lisabeth, D. Magid, G. M. Marcus, A. Marelli, D. B. Matchar, D. K. McGuire, E. R. Mohler, C. S. Moy, M. E. Mussolino, G. Nichol, N. P. Paynter, P. J. Schreiner, P. D. Sorlie, J. Stein, T. N. Turan, S. S. Virani, N. D. Wong, D. Woo, M. B. Turner; American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Executive summary: Heart disease and stroke statistics - 2013 update: A report from the American Heart Association. Circulation 127, 143-152 (2013).
2. F. G. Kushner, M. Hand, S. C. Smith Jr., S. B. King III, J. L. Anderson, E. M. Antman, S. R. Bailey, E. R. Bates, J. C. Blankenship, D. E. Casey, L. A. Green, J. S. Hochman, A. K. Jacobs, H. M. Krumholz, D. A. Morrison, J. P. Ornato, D. L. Pearle, E. D. Peterson, M. A. Sloan, P. L. Whitlow, D. O. Williams; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 120, 2271-2306 (2009).
3. P. J. Mason, A. K. Jacobs, J. E. Freedman, Aspirin resistance and atherothrombotic disease. J. Am. Coll. Cardiol. 46, 986-993 (2005).
4. L. Wallentin, P2Y12 inhibitors: Differences in properties and mechanisms of action and potential consequences for clinical use. Eur. Heart J. 30, 1964-1977 (2009).
5. S. D. Wiviott, E. Braunwald, C. H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, F. J. Neumann, D. Ardissino, S. De Servi, S. A. Murphy, J. Riesmeyer, G. Weerakkody, C. M. Gibson, E. M. Antman; TRITON-TIMI 38 Investigators, Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
6. L. Wallentin, R. C. Becker, A. Budaj, C. P. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K. W. Mahaffey, B. M. Scirica, A. Skene, P. G. Steg, R. F. Storey, R. A. Harrington; PLATO Investigators, A. Freij, M. Thorsén, Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
7. R. Mehran, S. J. Pocock, G. W. Stone, T. C. Clayton, G. D. Dangas, F. Feit, S. V. Manoukian, E. Nikolsky, A. J. Lansky, A. Kirtane, H. D. White, A. Colombo, J. H. Ware, J. W. Moses, E. M. Ohman, Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: A risk model from the ACUITY trial. Eur. Heart J. 30, 1457-1466 (2009).
8. M. C. Thel, R. M. Califf, B. E. Tardiff, L. H. Gardner, K. N. Sigmon, A. M. Lincoff, E. J. Topol, M. M. Kitt, J. C. Blankenship, J. E. Tcheng, Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to minimize platelet aggregation and coronary thrombosis. Am. J. Cardiol. 85, 427-434 (2000).
9. D. M. Yellon, D. L. Hausenloy, Myocardial reperfusion injury. N. Engl. J. Med. 357, 1121-1135 (2007).
10. G. Montalescot, S. D. Wiviott, E. Braunwald, S. A. Murphy, C. M. Gibson, C. H. McCabe, E. M. Antman; TRITON-TIMI 38 investigators, Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet 373, 723-731 (2009).
11. S. P. Jackson, S. M. Schoenwaelder, Antiplatelet therapy: In search of the 'magic bullet'. Nat. Rev. Drug Discov. 2, 775-789 (2003).
12. E. Kaczmarek, K. Koziak, J. Sévigny, J. B. Siegel, J. Anrather, A. R. Beaudoin, F. H. Bach, S. C. Robson, Identification and characterization of CD39/vascular ATP diphosphohydrolase. J. Biol. Chem. 271, 33116-33122 (1996).
13. A. J. Marcus, M. J. Broekman, J. H. Drosopoulos, N. Islam, T. N. Alyonycheva, L. B. Safier, K. A. Hajjar, D. N. Posnett, M. A. Schoenborn, K. A. Schooley, R. B. Gayle, C. R. Maliszewski, The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J. Clin. Invest. 99, 1351-1360 (1997).
14. A. J. Marcus, M. J. Broekman, J. H. Drosopoulos, K. E. Olson, N. Islam, D. J. Pinsky, R. Levi, Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin. Thromb. Hemost. 31, 234-246 (2005).
15. S. C. Robson, Y. Wu, X. Sun, C. Knosalla, K. Dwyer, K. Enjyoji, Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin. Thromb. Hemost. 31, 217-233 (2005).
16. A. F. Knowles, The GDA1-CD39 superfamily: NTPDases with diverse functions. Purinergic Signal. 7, 21-45 (2011).
17. L. Antonioli, P. Pacher, E. S. Vizi, G. Haskó, CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 19, 355-367 (2013).
18. C. Gachet, P2 receptors, platelet function and pharmacological implications. Thromb. Haemost. 99, 466-472 (2011).
19. M. J. Bours, E. L. Swennen, F. Di Virgilio, B. N. Cronstein, P. C. Dagnelie, Adenosine 5′-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol. Ther. 112, 358-404 (2006).
20. V. Kumar, A. Sharma, Adenosine: An endogenous modulator of innate immune system with therapeutic potential. Eur. J. Pharmacol. 616, 7-15 (2009).
21. K. Enjyoji, J. Sévigny, Y. Lin, P. S. Frenette, P. D. Christie, J. S. Esch, M. Imai, J. M. Edelberg, H. Rayburn, M. Lech, D. L. Beeler, E. Csizmadia, D. D. Wagner, S. C. Robson, R. D. Rosenberg, Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat. Med. 5, 1010-1017 (1999).
22. O. Guckelberger, X. F. Sun, J. Sévigny, M. Imai, E. Kaczmarek, K. Enjyoji, J. B. Kruskal, S. C. Robson, Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thromb. Haemost. 91, 576-586 (2004).
23. D. Köhler, T. Eckle, M. Faigle, A. Grenz, M. Mittelbronn, S. Laucher, M. L. Hart, S. C. Robson, C. E. Müller, H. K. Eltzschig, CD39/ectonucleoside triphosphate diphosphohydrolase-1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation 116, 1784-1794 (2007).
24. M. Cai, Z. M. Huttinger, H. He, W. Zhang, F. Li, L. A. Goodman, D. G. Wheeler, L. J. Druhan, J. L. Zweier, K. M. Dwyer, G. He, A. J. d'Apice, S. C. Robson, P. J. Cowan, R. J. Gumina, Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury. J. Mol. Cell. Cardiol. 51, 927-935 (2011).
25. D. G. Wheeler, M. E. Joseph, S. D. Mahamud, W. L. Aurand, P. J. Mohler, V. J. Pompili, K. M. Dwyer, M. B. Nottle, S. J. Harrison, A. J. d'Apice, S. C. Robson, P. J. Cowan, R. J. Gumina, Transgenic swine: Expression of human CD39 protects against myocardial injury. J. Mol. Cell. Cardiol. 52, 958-961 (2012).
26. D. J. Pinsky, M. J. Broekman, J. J. Peschon, K. L. Stocking, T. Fujita, R. Ramasamy, E. S. Connolly, J. Huang, S. Kiss, Y. Zhang, T. F. Choudhri, R. A. McTaggart, H. Liao, J. H. Drosopoulos, V. L. Price, A. J. Marcus, C. R. Maliszewski, Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J. Clin. Invest. 109, 1031-1040 (2002).
27. L. Belayev, L. Khoutorova, T. A. Deisher, A. Belayev, R. Busto, Y. Zhang, W. Zhao, M. D. Ginsberg, Neuroprotective effect of SolCD39, a novel platelet aggregation inhibitor, on transient middle cerebral artery occlusion in rats. Stroke 34, 758-763 (2003).
28. J. H. F. Drosopoulos, R. Kraemer, H. Shen, R. K. Upmacis, A. J. Marcus, E. Musi, Human solCD39 inhibits injury-induced development of neointimal hyperplasia. Thromb. Haemost. 103, 426-434 (2010).
29. V. V. Ivanenkov, J. Sevigny, T. L. Kirley, Trafficking and intracellular ATPase activity of human ecto-nucleotidase NTPDase3 and the effects of ER-targeted NTPDase3 on protein folding. Biochemistry 47, 9184-9197 (2008).
30. J. Lecka, M. S. Rana, J. Sévigny, Inhibition of vascular ectonucleotidase activities by the prodrugs ticlopidine and clopidogrel favours platelet aggregation. Br. J. Pharmacol. 161, 1150-1160 (2010).
31. B. P. Chadwick, A. M. Frischauf, The CD39-like gene family: Identification of three new human members (CD39L2, CD39L3, and CD39L4), their murine homologues, and a member of the gene family from Drosophila melanogaster. Genomics 50, 357-367 (1998).
32. R. Chen, S. S. Jeong, Functional prediction: Identification of protein orthologs and paralogs. Protein Sci. 9, 2344-2353 (2000).
33. J. H. Drosopoulos, M. J. Broekman, N. Islam, C. R. Maliszewski, R. B. Gayle III, A. J. Marcus, Site-directed mutagenesis of human endothelial cell ecto-ADPase/soluble CD39. Requirement of glutamate 174 and serine 218 for enzyme activity and inhibition of platelet recruitment. Biochemistry 39, 6936-6943 (2000).
34. V. V. Ivanenkov, J. Meller, T. L. Kirley, Characterization of disulfide bonds in human nucleoside triphosphate diphosphohydrolase 3 (NTPDase3): Implications for NTPDase structural modeling. Biochemistry 44, 8998-9012 (2005).
35. W. Kabsch, HG Mannherz, D. Suck, E. F. Pai, K. C. Holmes, Atomic structure of the actin: DNase I complex. Nature 347, 37-44 (1990).
36. F. Yang, C. A. Hicks-Berger, T. M. Smith, T. L. Kirley, Site-directed mutagenesis of human nucleoside triphosphate diphosphohydrolase 3: The importance of residues in the apyrase conserved regions. Biochemistry 40, 3943-3950 (2001).
37. R. Bonello, U. S. Tantry, R. Marcucci, R. Blindt, D. J. Angiolillo, R. Becker, D. L. Bhatt, M. Cattaneo, J. P. Collet, T. Cuisset, C. Gachet, G. Montalescot, L. K. Jennings, D. Kereiakes, D. Sibbing, D. Trenk, J. W. Van Werkum, F. Paganelli, M. J. Price, R. Waksman, P. A. Gurbel; Working Group on High On-Treatment Platelet Reactivity, Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56, 919-933 (2010).
38. G. T. Bleck, An alternative method for the rapid generation of stable high-expressing mammalian cell lines. BioProcess. J. 5, 1-7 (2006).
39. D. R. Abendschein, P. K. Baum, P. Verhallen, R. R. Eisenberg, M. E. Sullivan, D. R. Light, A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs. J. Pharmacol. Exp. Ther. 296, 567-572 (2001).
40. R. A. Kloner, No-reflow phenomenon: Maintaining vascular integrity. J. Cardiovasc. Pharmacol. Ther. 16, 244-250 (2011).
41. J. St Pierre, L. Y. Yang, K. Tamirisa, D. Scherrer, P. De Ciechi, E. Eisenberg, D. Tolunay, D. Abendschein, Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler. Thromb. Vasc. Biol. 19, 2263-2268 (1999).
42. B. S. Coller, Platelets and thrombolytic therapy. N. Engl. J. Med. 322, 33-42 (1990).
43. E. J. Haskel, S. R. Torr, K. C. Day, M. O. Palmier, T. C. Wun, B. E. Sobel, D. Abendschein, Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 84, 821-827 (1991).
44. J. S. Maayani, T. M. Tagliente, T. Schwarz, G. Martinelli, R. Martinez, L. Shore-Lesserson, The balance of concurrent aggregation and deaggregation processes in platelets is linked to differential occupancy of ADP receptor subtypes. Platelets 12, 83-93 (2001).
45. G. Stephens, M. He, C. Wong, M. Jurek, H. C. Luedemanna, G. Shapurian, K. Munnelly, C. Muir, P. B. Conley, D. R. Philips, P. Andre, Development of a perfusion chamber assay to study in real time the kinetics of thrombosis and the antithrombotic characteristics of antiplatelet drugs. Thromb. J. 10, 11 (2012).
46. G. I. Lunkes, D. S. Lunkes, D. Leal, M. D. C. Araujo, M. Correa, L. Becker, C. S. D. Rosa, V. M. Morsch, M. R. C. Schetinger, Effect of high glucose levels in human platelet NTPDase and 5′-nucleotidase activities. Diabetes Res. Clin. Pract. 81, 351-357 (2008).
47. J. P. Headrick, Ischemic preconditioning: Bioenergetic and metabolic changes and the role of endogenous adenosine. J. Mol. Cell. Cardiol. 28, 1227-1240 (1996).
48. S. S. Sugimoto, X. Lin, J. Lai, M. Okazaki, N. A. Das, W. Li, A. S. Krupnick, R. Chen, S. S. Jeong, G. A. Patterson, D. Kreisel, A. E. Gelman, Apyrase treatment prevents ischemia-reperfusion injury in rat lung isografts. J. Thorac. Cardiovasc. Surg. 138, 752-759 (2009).
49. Ö. Uluçkan, M. C. Eagleton, D. H. Floyd, E. A. Morgan, A. C. Hirbe, M. Kramer, N. Dowland, J. L. Prior, D. Piwnica-Worms, S. S. Jeong, R. Chen, K. Weilbaecher, APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J. Cell. Biochem. 104, 1311-1323 (2008).
50. A. A. Baykov, O. A. Evtushenko, S. M. Avaeva, A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay. Anal. Biochem. 171, 266-270 (1988).
51. A. J. Marcus, M. J. Broekman, J. H. Drosopoulos, N. Islam, D. J. Pinsky, C. Sesti, R. Levi, Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: Implications for ischemic vascular diseases. J. Pharmacol. Exp. Ther. 305, 9-16 (2003).